PTGX

Protagonist TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

30%

Probability

Target price

$125.00

+34.1% vs current

Most likely

Base case

45%

Probability

Target price

$107.00

+14.8% vs current

B-

Bear case

25%

Probability

Target price

$72.00

-22.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Sentiment stays cautiously constructive, but this should remain a monitoring-style memo rather than a high-conviction bullish call. Primary sources improved the setup with ICOTYDE approval on March 18, 2026 and the rusfertide opt-out election on April 28, 2026, both of which support non-dilutive economics and partner-led commercialization [#PR-2026-03-18] [#PR-2026-04-28]. However, the scheduled May 4, 2026 post-earnings follow-up did not yield a confirmed Q1 2026 earnings release or analyst revision signal in checked company/SEC sources, so there is no fresh earnings-surprise evidence to upgrade conviction. PTGX traded about 1.1% above the May 1 anchor price during May 4 trading, which looks more like steady event-driven positioning than a decisive post-print reaction.

RankAlpha Sentiment Codex - 2026-05-04

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystRusfertide opt-out election materially changes near-term cash and launch-risk profileHigh impact

On April 28, 2026, Protagonist said it exercised its rusfertide U.S. opt-out right with Takeda, making it eligible for $200 million upon the election, another $200 million upon U.S. approval, plus a $75 million approval milestone, while shifting U.S. commercialization responsibility to Takeda; that sharpens the near-term setup but still needs conversion into received cash and eventual approval [#PR-2026-04-28].

2026-09-30eventRusfertide FDA decision remains the main binary re-rating eventHigh impact

The April 28, 2026 company update said rusfertide remains under FDA Priority Review for adults with polycythemia vera with a PDUFA target action date in the third quarter of 2026; approval would unlock the second opt-out payment and a further approval milestone, while a delay or rejection would hit the core thesis [#PR-2026-04-28].

2026-12-31catalystICOTYDE approval adds a second partnered royalty-and-milestone growth legHigh impact

Protagonist disclosed on March 18, 2026 that FDA approved ICOTYDE for moderate-to-severe plaque psoriasis, triggering a $50 million milestone and leaving Protagonist eligible for 6% to 10% royalties plus up to $580 million of additional milestones; if launch uptake and follow-on indication studies progress, this can diversify value away from a single rusfertide outcome over time [#PR-2026-03-18].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology